Research programme: influenza virus transcriptase inhibitors - Shire
Latest Information Update: 22 Dec 2016
At a glance
- Originator ViroPharma
- Mechanism of Action DNA-directed RNA polymerase modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 22 Apr 1999 Preclinical development for Influenza virus infections in USA (Unknown route)